Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial

MLA

Mitsuru Sasako, et al. “Gastrectomy plus Chemotherapy versus Chemotherapy Alone for Advanced Gastric Cancer with a Single Non-Curable Factor (REGATTA): A Phase 3, Randomised Controlled Trial.” The Lancet Oncology, vol. 17, Mar. 2016, pp. 309–18. EBSCOhost, https://doi.org/10.1016/s1470-2045(15)00553-7.

APA

Mitsuru Sasako, Masanori Terashima, Junki Mizusawa, Byung Joo Park, Yukinori Kurokawa, Akinori Takagane, Han-Kwang Yang, Cho Hyun Park, Kazumasa Fujitani, Woo Jin Hyung, Toshimasa Tsujinaka, Takaki Yoshikawa, Sang-Uk Han, Young-Woo Kim, Do Joong Park, Yoshiaki Iwasaki, Seokyung Hahn, Kenichi Nakamura, & Yung-Jue Bang. (2016). Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. The Lancet Oncology, 17, 309–318. https://doi.org/10.1016/s1470-2045(15)00553-7

Chicago

Mitsuru Sasako, Masanori Terashima, Junki Mizusawa, Byung Joo Park, Yukinori Kurokawa, Akinori Takagane, Han-Kwang Yang, et al. 2016. “Gastrectomy plus Chemotherapy versus Chemotherapy Alone for Advanced Gastric Cancer with a Single Non-Curable Factor (REGATTA): A Phase 3, Randomised Controlled Trial.” The Lancet Oncology 17 (March): 309–18. doi:10.1016/s1470-2045(15)00553-7.